Compare IGA & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | IGA | SWKH |
|---|---|---|
| Founded | 2005 | 1996 |
| Country | United States | United States |
| Employees | N/A | 9 |
| Industry | Investment Managers | Diversified Financial Services |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.5M | 198.4M |
| IPO Year | N/A | N/A |
| Metric | IGA | SWKH |
|---|---|---|
| Price | $9.57 | $16.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | ★ 50.6K | 5.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 8.93% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $52.93 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.18 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.43 | $13.00 |
| 52 Week High | $10.12 | $18.66 |
| Indicator | IGA | SWKH |
|---|---|---|
| Relative Strength Index (RSI) | 30.49 | 46.25 |
| Support Level | $9.39 | $16.65 |
| Resistance Level | $9.87 | $17.03 |
| Average True Range (ATR) | 0.09 | 0.20 |
| MACD | -0.05 | 0.03 |
| Stochastic Oscillator | 9.27 | 67.07 |
Voya Global Advantage and Premium Opportunity Fund is a United States-based diversified, closed-end management investment company. The fund has two investment objectives. Its primary objective is to provide a high level of income, while the secondary objective is to seek capital appreciation. To achieve these objectives, the fund invests at least 80% of its managed assets in a portfolio of common stocks from various countries around the world, including the United States. Additionally, it uses an integrated derivatives strategies.
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.